account_balance
Investment manager · 13F filer · SEC CIK 1822947
Ally Bridge Group (NY) LLC
Reported value$77.6Mas of Jun 30, 2026
Positions23 10 new, 8 sold out
Top 10 weight64.8%NERV alone is 16%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
NERVMinerva Neurosciences Inc
15.6%Added +31%
PMNPromis Neurosciences Inc
10.5%Added +50%
TRAXFirst Tracks Biotherapeutics
7.4%New
AXSMAxsome Therapeutics Inc
5.2%New
ASMBAssembly Biosciences Inc
5.0%New
WHWKWhitehawk Therapeutics Inc
4.8%
EWTXEdgewise Therapeutics Inc
4.4%Trimmed −48%
CLYMClimb Bio Inc
4.2%New
KURAKura Oncology Inc
4.1%New
CTMXCytomx Therapeutics Inc.
3.7%Trimmed −14%
AVTXAvalo Therapeutics Inc
3.6%New
PALIPalisade Bio Inc
3.3%New
NERVMinerva Neurosciences Inc
15.6%Added +31%
PMNPromis Neurosciences Inc
10.5%Added +50%
TRAXFirst Tracks Biotherapeutics
7.4%New
AXSM5.2%ASMB5.0%WHWK4.8%EWTX4.4%CLYM4.2%KURA4.1%CTMX3.7%AVTX3.6%PALI3.3%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
NERV Minerva Neurosciences Inc 15.6% Added +31%PMN Promis Neurosciences Inc 10.5% Added +50%TRAX First Tracks Biotherapeutics 7.4% NewAXSM Axsome Therapeutics Inc 5.2% NewASMB Assembly Biosciences Inc 5.0% NewWHWK Whitehawk Therapeutics Inc 4.8% HeldEWTX Edgewise Therapeutics Inc 4.4% Trimmed −48%CLYM Climb Bio Inc 4.2% NewKURA Kura Oncology Inc 4.1% NewCTMX Cytomx Therapeutics Inc. 3.7% Trimmed −14%AVTX Avalo Therapeutics Inc 3.6% NewPALI Palisade Bio Inc 3.3% New
What changed